Immutep's IMP761 Shows Positive Results in Autoimmune Disease Trial.
ByAinvest
Monday, Dec 22, 2025 8:08 am ET1min read
IMMP--
Immutep Limited reports positive results from the first-in-human Phase I study of IMP761, a LAG-3 agonist antibody for autoimmune diseases. The single-ascending dose portion of the trial has reached 2.5 and 7 mg/kg levels, showing a dose-dependent immunosuppressive effect and favorable safety profile. The substantial reduction in T-cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseases. The trial will continue as planned, with further updates and data presentation anticipated in 1H CY2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet